Loading stock…

Revvity, Inc. (RVTY) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Revvity, Inc.

RVTYMarket cap $17BPrice $153.3

Country🇺🇸United States

SectorHealthcare

IndustryLife Sciences

Makes the tools and reagents scientists use to discover drugs, screen newborns for genetic diseases, and diagnose cancer. Formerly PerkinElmer, it rebranded after selling its instruments arm, now betting fully on life sciences and diagnostics.

In Bastion Portfolios?

52W Return+64%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-5%2

Revenue Forecast

Rev CAGR (1y)-0%2

Rev CAGR (3y)+4%3

Rev CAGR (5y)+5%5

Earnings Forecast

EPS Growth Y+1+159%10

EPS Growth Y+2+10%7

EPS Growth Y+3+9%6

Quality

Margins

EBIT Margin16%6

Net Income Margin8%5

Free Cash Flow Margin19%8

Debt

Net Debt/EBITDA2.54

Efficiency

ROE3%2

ROA2%4

Earnings Stability22

GEAR+VERY WEAK14

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)282

P/E Ratio (Forward 3y)242

P/BV2.46

EV Multiples

EV/EBITDA Fwd222

EV/EBIT Fwd243

Yield

Free Cash Flow Yield3.3%5

Dividend Yield0.2%1

Momentum

Short term

1 month return+18%10

3 month return+37%10

YTD return+59%10

Mid term

Price vs 52wHigh92%9

1 year return+69%9

Long term

3 year return+44%5

5 year return-9%3

Risk Shield

Price Risk

Beta1.04

Volatility39%5

Free Cash Flow

Free Cash Flow Margin19%8

Free Cash Flow Yield3.3%5

Quality

ROCE4%3

Earnings Stability22

Net Debt/EBITDA2.54

02Growth

Is it actually growing, and how fast?

RVTYRevvity

Revenue FY25$2.9B

GROWTH RATING↗

WEAK29 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-5%2

Revenue, next 1Y-0%2

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+5%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+159%10

EPS growth, FY27E+10%7

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 10%/yr vs revenue 4%/yr), so margins should widen.

WATCH

After shrinking over the last 3 years, revenue is set to grow 4%/yr from here.

Over five years revenue is set to grow 5%/yr, about average versus companies worldwide.5/10

WEAKNESSES

Growth is the weak spot here, trailing 71% of companies worldwide.

Revenue fell 5%/yr over the last 3 years, behind 80% of companies worldwide.2/10

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

BOTTOM LINE

Margin Expander

Growth is a weak point here: a business that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG85 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+18%10

3-month return+37%10

YTD return+59%10

MID & LONG-TERM▾SCORE

% of 52-week high92%9

1-year return+69%9

3-year return+44%5

5-year return-9%3

MOMENTUM ASSESSMENT

STRENGTHS

It's up 69% over the past year, now 8% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+18%), over three months (+37%) and so far this year (+59%).

WATCH

Average long-term results. Multi-year returns are middling (+44% over three years and -9.3% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Revvity. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

RVTYRevvity

Revenue FY25$2.9B

GROWTH RATING↗

WEAK29 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-5%2

Revenue, next 1Y-0%2

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+5%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+159%10

EPS growth, FY27E+10%7

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 10%/yr vs revenue 4%/yr), so margins should widen.

WATCH

After shrinking over the last 3 years, revenue is set to grow 4%/yr from here.

Over five years revenue is set to grow 5%/yr, about average versus companies worldwide.5/10

WEAKNESSES

Growth is the weak spot here, trailing 71% of companies worldwide.

Revenue fell 5%/yr over the last 3 years, behind 80% of companies worldwide.2/10

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

BOTTOM LINE

Margin Expander

Growth is a weak point here: a business that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG85 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+18%10

3-month return+37%10

YTD return+59%10

MID & LONG-TERM▾SCORE

% of 52-week high92%9

1-year return+69%9

3-year return+44%5

5-year return-9%3

MOMENTUM ASSESSMENT

STRENGTHS

It's up 69% over the past year, now 8% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+18%), over three months (+37%) and so far this year (+59%).

WATCH

Average long-term results. Multi-year returns are middling (+44% over three years and -9.3% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Revvity. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community